Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $29

JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $29

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $33 to $29.

byBenzinga Newsdesk

December 6, 2022

1 minute read

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $33 to $29.

Chardan Capital Maintains Buy on Immunome, Lowers Price Target to $8

By Benzinga Newsdesk

March 17, 4:36 AM

Chardan Capital analyst Matthew Barcus maintains Immunome (NASDAQ:IMNM) with a Buy and lowers the price target from $9 to $8.

IMNM

Alibaba, NVIDIA And 3 Stocks To Watch Heading Into Thursday

By Lisa Levin

February 23, 5:02 AM

With US futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

BABA

Paul Tudor Jones Trades These 2 Equity REITs

By Robert Kuczmarski

October 16, 10:00 AM

Tudor Investment Corporation CEO Paul Tudor Jones, who founded the company in 1980, is also known for his prediction of Black Monday and for starting the Robin Hood Foundation.

CCI

Why F5 Stock Is Rising After The Bell?

By Adam Eckert

July 24, 4:36 PM

Shares of cloud application services and security company F5 Inc (NASDAQ: FFIV) are trading higher in Monday's after-hours session after the company reported better-than-expected

FFIV

JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $29

Related Posts

Chardan Capital Maintains Buy on Immunome, Lowers Price Target to $8

Alibaba, NVIDIA And 3 Stocks To Watch Heading Into Thursday

Paul Tudor Jones Trades These 2 Equity REITs

Why F5 Stock Is Rising After The Bell?